Autoimmune Disease Testing Market Size, Share, Growth Opportunity Analysis Report by Test Type (Antinuclear Antibody (ANA) Tests, Autoantibody Tests, C-reactive Protein (CRP) Tests, Erythrocyte Sedimentation Rate (ESR) Tests, Rheumatoid Factor (RF) Tests, Immunologic Tests, Enzyme-linked Immunosorbent Assay (ELISA), Others), Disease Type, Product Type, Technology, Sample Type, Sample Type, End User, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035
|
Market Structure & Evolution
|
- The global autoimmune disease testing market is valued at nearly USD 4.6 billion in 2025.
- The market is projected to grow at a CAGR of nearly 6.8% during the forecast period of 2025 to 2035.
|
|
Segmental Data Insights
|
- The autoantibody tests segment accounts for nearly 40% of the global autoimmune disease testing market in 2025, driven by increased prevalence of autoimmune disorders and advancements in test accuracy.
|
|
Demand Trends
|
- Growing demand for early diagnosis and personalized treatment is driving adoption of advanced autoimmune disease testing to support precision medicine and improved patient outcomes.
- Integration of AI, machine learning, and digital diagnostics is further boosting market growth, enabling faster, more accurate results and streamlining the testing process for better clinical decision-making.
|
|
Competitive Landscape
|
- The global autoimmune disease testing market is highly consolidated, with the top five players accounting for over 50% of the market share in 2025.
|
|
Strategic Development
|
- In April 2025, Abbott Laboratories is excited to announce the launch of its next generation autoimmune diagnostic platform, ImmunoSure DX,.
- In March 2025, Siemens Healthineers announced the launching of its novel diagnostic platform, "AutoDetect Ultra", aimed to simplify detection of autoimmune diseases
|
|
Future Outlook & Opportunities
|
- Global autoimmune disease testing market is likely to create the total forecasting opportunity of nearly USD 4.3 Bn till 2035
- North America is most attractive region
|
Autoimmune Disease Testing Market Size, Share, and Growth
The global autoimmune disease testing market is experiencing robust growth, with its estimated value of USD 4.6 billion in the year 2025 and USD 8.9 billion by 2035, registering a CAGR of 6.8%. North America leads the market with market share of 46% with USD 2.1 billion revenue.

Leaders like Thermo Fisher, Abbott, and Bio-Rad lead innovation of multiplex immunoassays, NGS, and AI-based diagnostics. These tools support faster and more accurate detection of diseases like lupus and RA, which supports earlier intervention and personalized treatment options as the rate of prevalence continues to rise for autoimmune patients.
Autoimmune disease testing is of growing importance to important parts of healthcare diagnostics, drug development and personalized medicine. Multiplex immunoassay platforms are the current market leaders with their high sensitivity, automation and defined turnaround times. For instance, in early 2024, Bio-Rad Laboratories made the announcement of new AI-integrated immunoassay systems that can simultaneously detect multiple autoimmune markers with improved accuracy plus predictive analytics for clinical and research studies.
In addition, AI and machine learning are already helping to interpreting these tests, minimizing the lag in diagnosis and improving care outcomes for patients, especially those in less studied or underdiagnosed/misdiagnosed conditions. Increasing access to these tools remains a priority and the major testing companies are beginning to partner with public health agencies, payers and rural clinics, to create low-cost, scalable diagnostics for underserved patients.
Furthermore, beyond simply detection, there is also a focus on improving patient quality of life, and earlier treatment interventions that ultimately lessen longer term costs of care. With smarter diagnostics, there is more focus on predictive - than reactive - care that helps patients avoid years of distress, and the risks of everlasting autoimmune injury.
Moreover, newly emerged applications in early diagnosis, treatment monitoring, and drug development, are also contributing to the growing need for autoimmune disease testing. Diagnostic companies are developing a biomarker panel as well as machine learning techniques that facilitate the diagnosis of complex autoimmune conditions including lupus, rheumatoid arthritis, multiple sclerosis, allowing for more targeted patient management and treatment outcomes.

Autoimmune Disease Testing Market Dynamics and Trends
Drivers: Precision Diagnostics and Rising Autoimmune Prevalence Fuel Autoimmune Disease Testing Market Expansion
- Due to rising diagnosis in historically hard to detect diseases, such as lupus, rheumatoid arthritis, and multiple sclerosis, the autoimmune disease testing market is seeing growth. With healthcare providers deploying new testing methodologies (e.g., biomarker analyses, genetic testing, multiplex immunoassays), they are much better able to diagnose these diseases (and other autoimmune diseases) accurately and identify them early.
- The patient benefit of early diagnosis is that they receive their desired treatment sooner, improve their condition more quickly and can keep the long-term medical costs to a minimum.
- Consequently, all medical test results can be analyzed, especially in the recent COVID-19 environment, using AI and machine learning tools to make test results more actionable for doctors. The growth in this market is likely to occur steadily as people's awareness of autoimmune diseases continues to proliferate, as technology improves the routing and turnaround time of testing, and as affordable, reliable diagnostics are expanded and implemented in both developed and developing nations.
Restraints: High Testing Costs and Diagnostic Complexity Limit Widespread Adoption in Autoimmune Disease Testing Market
- The autoimmune disease testing market is progressing but continues to face many barriers. Chief among these barriers is the cost of advanced tests, such as biomarker panels, genetic profiling, and multiplex assays. These tests will be a hard pill to swallow financially whether they are purchased on an out-of-pocket basis, or even for patients in low-and-middle-income countries or patients with inadequate health care coverage in high-income countries.
- Furthermore, since autoimmune disease often presents with complex convoluted serious array of symptoms, which overlap with other illnesses, there can misdiagnosis or delayed diagnosis if the general practitioner has no access to tests or if they receive inadequate training.
- Even though the awareness and access to autoimmune disease information and retail testing are increasing in some contexts, the absence of widely-accepted testing methods and the limited availability of diagnostic infrastructure in parts of the world will continue to postpone any wider proposition of autoimmune disease diagnostics.
Opportunity: Emerging Biomarkers and Personalized Medicine Unlock New Opportunities in Autoimmune Disease Testing Market
- The future of autoimmune disease testing is bright with new discoveries in biomarkers, and the rise of personalized medicine. Scientists are discovering new, specific biomarkers to identify autoimmune diseases much earlier than a traditional test and in a much more specific manner. There are opportunities to develop new diagnostic panels for specific diseases such as lupus, Crohn’s disease, and multiple sclerosis.
- Furthermore, the shift to personalized healthcare means that there is increased need for tests to inform treatment decisions based on a patient’s immune profile and their genetic profile through molecular diagnostics. With the incorporation of artificial intelligence into diagnostic platforms it will be possible to interpret complex information in a smart, efficient way. These new tools will assist patients in receiving better outcomes, and allow diagnostic companies to develop new opportunities in precision healthcare and companion diagnostics.
Key Trend: Integration of Multi-Omics and AI Enhancing Diagnostic Accuracy in Autoimmune Disease Testing Market
- The field of autoimmune illness diagnosis is now changing significantly toward multi-omics approaches including genomics, proteomics, transcriptomics, and metabolomics to provide a more thorough knowledge of immune-mediated illnesses. More detail and integration enable a more precise and early diagnosis especially of disorders that manifest with comparable or hazy symptoms among those impacted.
- Further, multi-omic approaches are even more relevant when utilizing artificial intelligence and machine learning multi-omic data can be processed faster and with greater accuracy, allowing pre-symptomatic patterns to be sensed and potential treatments determined in an expedited manner. The ability for earlier-stage diagnosis and treatment alongside rising autoimmune disease prevalence, in combination with patients requiring more true data-driven care, makes this transition particularly timely.
- Lastly, research laboratories, diagnostic companies, and biotechnology companies are collaborating, along with other relevant stakeholders, to bring these new, more sophisticated methods of testing from laboratories into clinical practice and continuing to develop next-generation diagnostics for autoimmune disease.
Autoimmune Disease Testing Market Analysis and Segmental Data

Based on Test Type, Autoantibody Tests hold the Largest Share
- Autoantibody tests are the largest segment in the autoimmune disease testing market because they are broad spectrum antigen testing diagnostics used to diagnose many of the most common autoimmune diseases (i.e. rheumatoid arthritis, lupus, autoimmune thyroid disease) require autoantibody tests because they identify the body’s antibodies that mistakenly attack the body’s tissues and organs, which is perhaps the most definitive criteria for determining if a person has an autoimmune disease.
- Additionally, autoantibody tests are relatively cheap, easy to conduct, and play an established role in clinical practice guidelines which is the reason why physicians instinctively order autoantibody tests as a first tier diagnostic test.
- Moreover, autoantibody tests are readily available as they are present in both hospital labs and private diagnostic centers, which have created an accessible and scalable spirit. With an increasing global interest and awareness around autoimmune disease and availability for screening, autoantibody tests will continue to account for the largest share of the autoimmune disease testing market as long as there is a demand for reliable, timely and cheap tests.
North America Dominates Autoimmune disease testing Market in 2025 and beyond
- North America is the leading autoimmune disease testing market due to the large rate of autoimmune disorders, an established healthcare system with greater access to advanced diagnostic technologies. In the U.S. and Canada, individuals generally have well visits that could lead them to get tested for autoimmune diseases more frequently than citizens in other parts of the world.
- There is also numerous reputable biotechnology and diagnostic companies located in North America dedicated to research and innovation, developing better testing methods for autoimmune diseases.
- In addition, there are reimbursement policies in place related to healthcare that support autoimmune disease test, and patient awareness campaigns promoting the use of tests. Overall, North America will remain the largest market compared to the rest of the world with respect to autoimmune disease diagnostics.
Autoimmune Disease Testing Market Ecosystem
The autoimmune disease testing market is highly consolidated. The market concentration is medium. The Tier 1 players include Roche Diagnostics, Thermo Fisher Scientific (Phadia AB), Abbott Laboratories, Siemens Healthineers, and Bio‑Rad Laboratories, Inc. who have a significant share because of their broad product portfolio available worldwide, alongside the fact that they offer these products alongside their own reagents and many with varying levels of R&D. Porter's five forces; buyer concentration is medium as the demand is end-user hospitals, diagnostic labs and clinics. Supplier Concentration is high because there are few manufacturers who specialize in these reagents and equipment.

Recent Development and Strategic Overview:
- In April 2025, Abbott Laboratories is excited to announce the launch of its next generation autoimmune diagnostic platform, ImmunoSure DX, designed to facilitate earlier and more accurate identification of complex autoimmune disorders. With advanced multiplex autoantibody profiling combined with AI-assisted interpretation of results, ImmunoSure DX accurately identifies overlapping autoimmune signals like never before.
- In March 2025, Siemens Healthineers announced the launching of its novel diagnostic platform, "AutoDetect Ultra", aimed to simplify detection of autoimmune diseases through laboratory automation and machine learning based test analytics. AutoDetect Ultra allows for high throughput testing for multiple autoantibodies while reducing human error and turnaround time. The initial implementation in several leading academic hospitals in Germany, India and Brazil reported up to 40% faster diagnosis, and 15% has improved result accuracy on test results in patients with early-stage rheumatoid arthritis and systemic autoimmune disorders.
Report Scope
|
Attribute
|
Detail
|
|
Market Size in 2025
|
USD 4.6 Bn
|
|
Market Forecast Value in 2035
|
USD 8.9 Bn
|
|
Growth Rate (CAGR)
|
6.8%
|
|
Forecast Period
|
2025 – 2035
|
|
Historical Data Available for
|
2021 – 2024
|
|
Market Size Units
|
USD Bn for Value
Million Units for Volume
|
|
Report Format
|
Electronic (PDF) + Excel
|
|
Regions and Countries Covered
|
|
North America
|
Europe
|
Asia Pacific
|
Middle East
|
Africa
|
South America
|
- United States
- Canada
- Mexico
|
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Nordic Countries
- Poland
- Russia & CIS
|
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- Indonesia
- Malaysia
- Thailand
- Vietnam
|
- Turkey
- UAE
- Saudi Arabia
- Israel
|
- South Africa
- Egypt
- Nigeria
- Algeria
|
|
|
Companies Covered
|
|
|
- Danaher Corporation
- EUROIMMUN AG
- Exagen Inc.
- F. Hoffmann-La Roche Ltd
|
- Grifols, S.A.
- Hologic, Inc.
- Inova Diagnostics, Inc.
- Myriad Genetics, Inc.
- ORGENTE
|
C Diagnostika GmbH
|
ed
Inc.
|
- Trinity Biotech plc
- Werfen Life Group
- Other key Players
|
Autoimmune Disease Testing Market Segmentation and Highlights
|
Segment
|
Sub-segment
|
|
By Test Type
|
- Antinuclear Antibody (ANA) Tests
- Autoantibody Tests
- C-reactive Protein (CRP) Tests
- Erythrocyte Sedimentation Rate (ESR) Tests
- Rheumatoid Factor (RF) Tests
- Immunologic Tests
- Enzyme-linked Immunosorbent Assay (ELISA)
- Others
|
|
By Disease Type
|
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Celiac Disease
- Sjögren’s Syndrome
- Thyroiditis
- Scleroderma
- Type 1 Diabetes
- Others
|
|
By Product Type
|
- Consumables & Assay Kits
- Instruments
- Software & Services
- Others
|
|
By Technology
|
- Immunoassay
- Indirect Immunofluorescence
- Multiplex Assay
- Hemagglutination Tests
- Others
|
|
By Sample Type
|
- Blood
- Urine
- Saliva
- Others
|
|
By Sample Type
|
- Manual Tests
- Semi-Automated Tests
- Fully Automated Tests
|
|
By End User
|
- Hospitals & Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Ambulatory Care Centers
- Others
|
Frequently Asked Questions
The global autoimmune disease testing market was valued at USD 4.6 Bn in 2025
The global autoimmune disease testing market industry is expected to grow at a CAGR of 6.8% from 2025 to 2035.
Growing rates of autoimmune diseases and the need of early, correct diagnosis are fueling demand, backed by developments in diagnostic techniques and biomarkers.
Autoantibody tests with nearly 40% of the total market, contributed to the largest share of the autoimmune disease testing market business in 2025.
North America is a more attractive region for vendors.
Key players in the autoimmune disease testing market include Abbott Laboratories, Beckman Coulter, Inc., bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, EUROIMMUN AG, Exagen Inc., F. Hoffmann-La Roche Ltd, Grifols, S.A., Hologic, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., ORGENTEC Diagnostika GmbH, Phadia AB (a Thermo Fisher brand), Quest Diagnostics Incorporated, Siemens Healthineers, SRL Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech plc, Werfen Life Group, and other key players, along with several other key players contributing to market growth through innovation, strategic partnerships, and global expansion.
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global Autoimmune Disease Testing Market Outlook
- 2.1.1. Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2025-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 3. Industry Data and Premium Insights
- 3.1. Autoimmune Disease Testing Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Source Roadmap and Developments
- 3.4. Trade Analysis
- 3.4.1. Import & Export Analysis, 2025
- 3.4.2. Top Importing Countries
- 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
- 3.5.1. Manufacturer
- 3.5.2. Supply Chain
- 3.5.3. End Consumer
- 3.6. Raw Material Analysis
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Precision Diagnostics and Rising Autoimmune Prevalence Fuel Global Autoimmune Disease Testing Market Expansion
- 4.1.2. Restraints
- 4.1.2.1. High Testing Costs and Diagnostic Complexity Limit Widespread Adoption in Autoimmune Disease Testing Market
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
- 4.4.1. Raw Components Sourcing
- 4.4.2. Manufacturing and Processing
- 4.4.3. Wholesalers/ E-commerce Platform
- 4.4.4. End-use/ Customers
- 4.5. Cost Structure Analysis
- 4.5.1. Parameter’s Share for Cost Associated
- 4.5.2. COGP vs COGS
- 4.5.3. Profit Margin Analysis
- 4.6. Pricing Analysis
- 4.6.1. Regional Pricing Analysis
- 4.6.2. Segmental Pricing Trends
- 4.6.3. Factors Influencing Pricing
- 4.7. Porter’s Five Forces Analysis
- 4.8. PESTEL Analysis
- 4.9. Global Autoimmune Disease Testing Market Demand
- 4.9.1. Historical Market Size – (Volume - Million Units and Value - USD Bn), 2021-2024
- 4.9.2. Current and Future Market Size – (Volume - Million Units and Value - USD Bn), 2025–2035
- 4.9.2.1. Y-o-Y Growth Trends
- 4.9.2.2. Absolute $ Opportunity Assessment
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 6. Global Autoimmune Disease Testing Market Analysis, by Test Type
- 6.1. Key Segment Analysis
- 6.2. Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Test Type, 2021-2035
- 6.2.1. Antinuclear Antibody (ANA) Tests
- 6.2.2. Autoantibody Tests
- 6.2.3. C-reactive Protein (CRP) Tests
- 6.2.4. Erythrocyte Sedimentation Rate (ESR) Tests
- 6.2.5. Rheumatoid Factor (RF) Tests
- 6.2.6. Immunologic Tests
- 6.2.7. Enzyme-linked Immunosorbent Assay (ELISA)
- 6.2.8. Others
- 7. Global Autoimmune Disease Testing Market Analysis, by Disease Type
- 7.1. Key Segment Analysis
- 7.2. Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Disease Type, 2021-2035
- 7.2.1. Systemic Lupus Erythematosus
- 7.2.2. Rheumatoid Arthritis
- 7.2.3. Celiac Disease
- 7.2.4. Sjögren’s Syndrome
- 7.2.5. Thyroiditis
- 7.2.6. Scleroderma
- 7.2.7. Type 1 Diabetes
- 7.2.8. Others
- 8. Global Autoimmune Disease Testing Market Analysis, by Product Type
- 8.1. Key Segment Analysis
- 8.2. Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Product Type, 2021-2035
- 8.2.1. Consumables & Assay Kits
- 8.2.2. Instruments
- 8.2.3. Software & Services
- 8.2.4. Others
- 9. Global Autoimmune Disease Testing Market Analysis, by Technology
- 9.1. Key Segment Analysis
- 9.2. Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Technology, 2021-2035
- 9.2.1. Immunoassay
- 9.2.2. Indirect Immunofluorescence
- 9.2.3. Multiplex Assay
- 9.2.4. Hemagglutination Tests
- 9.2.5. Others
- 10. Global Autoimmune Disease Testing Market Analysis, by Sample Type
- 10.1. Key Segment Analysis
- 10.2. Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Sample Type, 2021-2035
- 10.2.1. Blood
- 10.2.2. Urine
- 10.2.3. Saliva
- 10.2.4. Others
- 11. Global Autoimmune Disease Testing Market Analysis, by Method Type
- 11.1. Key Segment Analysis
- 11.2. Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Method Type, 2021-2035
- 11.2.1. Manual Tests
- 11.2.2. Semi-Automated Tests
- 11.2.3. Fully Automated Tests
- 12. Global Autoimmune Disease Testing Market Analysis, by End User
- 12.1. Key Segment Analysis
- 12.2. Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by End User, 2021-2035
- 12.2.1. Hospitals & Clinics
- 12.2.2. Diagnostic Laboratories
- 12.2.3. Academic & Research Institutes
- 12.2.4. Ambulatory Care Centers
- 12.2.5. Others
- 13. Global Autoimmune Disease Testing Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Region, 2021-2035
- 13.2.1. North America
- 13.2.2. Europe
- 13.2.3. Asia Pacific
- 13.2.4. Middle East
- 13.2.5. Africa
- 13.2.6. South America
- 14. North America Global Autoimmune Disease Testing Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 14.3.1. Test Type
- 14.3.2. Disease Type
- 14.3.3. Product Type
- 14.3.4. Technology
- 14.3.5. Sample Type
- 14.3.6. Method Type
- 14.3.7. End User
- 14.3.8. Country
- 14.3.8.1. USA
- 14.3.8.2. Canada
- 14.3.8.3. Mexico
- 14.4. USA Global Autoimmune Disease Testing Market
- 14.4.1. Country Segmental Analysis
- 14.4.2. Test Type
- 14.4.3. Disease Type
- 14.4.4. Product Type
- 14.4.5. Technology
- 14.4.6. Sample Type
- 14.4.7. Method Type
- 14.4.8. End User
- 14.5. Canada Global Autoimmune Disease Testing Market
- 14.5.1. Country Segmental Analysis
- 14.5.2. Test Type
- 14.5.3. Disease Type
- 14.5.4. Product Type
- 14.5.5. Technology
- 14.5.6. Sample Type
- 14.5.7. Method Type
- 14.5.8. End User
- 14.6. Mexico Global Autoimmune Disease Testing Market
- 14.6.1. Country Segmental Analysis
- 14.6.2. Test Type
- 14.6.3. Disease Type
- 14.6.4. Product Type
- 14.6.5. Technology
- 14.6.6. Sample Type
- 14.6.7. Method Type
- 14.6.8. End User
- 15. Europe Global Autoimmune Disease Testing Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 15.3.1. Test Type
- 15.3.2. Disease Type
- 15.3.3. Product Type
- 15.3.4. Technology
- 15.3.5. Sample Type
- 15.3.6. Method Type
- 15.3.7. End User
- 15.3.8. Country
- 15.3.8.1. Germany
- 15.3.8.2. United Kingdom
- 15.3.8.3. France
- 15.3.8.4. Italy
- 15.3.8.5. Spain
- 15.3.8.6. Netherlands
- 15.3.8.7. Nordic Countries
- 15.3.8.8. Poland
- 15.3.8.9. Russia & CIS
- 15.3.8.10. Rest of Europe
- 15.4. Germany Global Autoimmune Disease Testing Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Test Type
- 15.4.3. Disease Type
- 15.4.4. Product Type
- 15.4.5. Technology
- 15.4.6. Sample Type
- 15.4.7. Method Type
- 15.4.8. End User
- 15.5. United Kingdom Global Autoimmune Disease Testing Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Test Type
- 15.5.3. Disease Type
- 15.5.4. Product Type
- 15.5.5. Technology
- 15.5.6. Sample Type
- 15.5.7. Method Type
- 15.5.8. End User
- 15.6. France Global Autoimmune Disease Testing Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Test Type
- 15.6.3. Disease Type
- 15.6.4. Product Type
- 15.6.5. Technology
- 15.6.6. Sample Type
- 15.6.7. Method Type
- 15.6.8. End User
- 15.7. Italy Global Autoimmune Disease Testing Market
- 15.7.1. Country Segmental Analysis
- 15.7.2. Test Type
- 15.7.3. Disease Type
- 15.7.4. Product Type
- 15.7.5. Technology
- 15.7.6. Sample Type
- 15.7.7. Method Type
- 15.7.8. End User
- 15.8. Spain Global Autoimmune Disease Testing Market
- 15.8.1. Country Segmental Analysis
- 15.8.2. Test Type
- 15.8.3. Disease Type
- 15.8.4. Product Type
- 15.8.5. Technology
- 15.8.6. Sample Type
- 15.8.7. Method Type
- 15.8.8. End User
- 15.9. Netherlands Global Autoimmune Disease Testing Market
- 15.9.1. Country Segmental Analysis
- 15.9.2. Test Type
- 15.9.3. Disease Type
- 15.9.4. Product Type
- 15.9.5. Technology
- 15.9.6. Sample Type
- 15.9.7. Method Type
- 15.9.8. End User
- 15.10. Nordic Countries Global Autoimmune Disease Testing Market
- 15.10.1. Country Segmental Analysis
- 15.10.2. Test Type
- 15.10.3. Disease Type
- 15.10.4. Product Type
- 15.10.5. Technology
- 15.10.6. Sample Type
- 15.10.7. Method Type
- 15.10.8. End User
- 15.11. Poland Global Autoimmune Disease Testing Market
- 15.11.1. Country Segmental Analysis
- 15.11.2. Test Type
- 15.11.3. Disease Type
- 15.11.4. Product Type
- 15.11.5. Technology
- 15.11.6. Sample Type
- 15.11.7. Method Type
- 15.11.8. End User
- 15.12. Russia & CIS Global Autoimmune Disease Testing Market
- 15.12.1. Country Segmental Analysis
- 15.12.2. Test Type
- 15.12.3. Disease Type
- 15.12.4. Product Type
- 15.12.5. Technology
- 15.12.6. Sample Type
- 15.12.7. Method Type
- 15.12.8. End User
- 15.13. Rest of Europe Global Autoimmune Disease Testing Market
- 15.13.1. Country Segmental Analysis
- 15.13.2. Test Type
- 15.13.3. Disease Type
- 15.13.4. Product Type
- 15.13.5. Technology
- 15.13.6. Sample Type
- 15.13.7. Method Type
- 15.13.8. End User
- 16. Asia Pacific Global Autoimmune Disease Testing Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. East Asia Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Test Type
- 16.3.2. Disease Type
- 16.3.3. Product Type
- 16.3.4. Technology
- 16.3.5. Sample Type
- 16.3.6. Method Type
- 16.3.7. End User
- 16.3.8. Country
- 16.3.8.1. China
- 16.3.8.2. India
- 16.3.8.3. Japan
- 16.3.8.4. South Korea
- 16.3.8.5. Australia and New Zealand
- 16.3.8.6. Indonesia
- 16.3.8.7. Malaysia
- 16.3.8.8. Thailand
- 16.3.8.9. Vietnam
- 16.3.8.10. Rest of Asia-Pacific
- 16.4. China Global Autoimmune Disease Testing Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Test Type
- 16.4.3. Disease Type
- 16.4.4. Product Type
- 16.4.5. Technology
- 16.4.6. Sample Type
- 16.4.7. Method Type
- 16.4.8. End User
- 16.5. India Global Autoimmune Disease Testing Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Test Type
- 16.5.3. Disease Type
- 16.5.4. Product Type
- 16.5.5. Technology
- 16.5.6. Sample Type
- 16.5.7. Method Type
- 16.5.8. End User
- 16.6. Japan Global Autoimmune Disease Testing Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Test Type
- 16.6.3. Disease Type
- 16.6.4. Product Type
- 16.6.5. Technology
- 16.6.6. Sample Type
- 16.6.7. Method Type
- 16.6.8. End User
- 16.7. South Korea Global Autoimmune Disease Testing Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Test Type
- 16.7.3. Disease Type
- 16.7.4. Product Type
- 16.7.5. Technology
- 16.7.6. Sample Type
- 16.7.7. Method Type
- 16.7.8. End User
- 16.8. Australia and New Zealand Global Autoimmune Disease Testing Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Test Type
- 16.8.3. Disease Type
- 16.8.4. Product Type
- 16.8.5. Technology
- 16.8.6. Sample Type
- 16.8.7. Method Type
- 16.8.8. End User
- 16.9. Indonesia Global Autoimmune Disease Testing Market
- 16.9.1. Country Segmental Analysis
- 16.9.2. Test Type
- 16.9.3. Disease Type
- 16.9.4. Product Type
- 16.9.5. Technology
- 16.9.6. Sample Type
- 16.9.7. Method Type
- 16.9.8. End User
- 16.10. Malaysia Global Autoimmune Disease Testing Market
- 16.10.1. Country Segmental Analysis
- 16.10.2. Test Type
- 16.10.3. Disease Type
- 16.10.4. Product Type
- 16.10.5. Technology
- 16.10.6. Sample Type
- 16.10.7. Method Type
- 16.10.8. End User
- 16.11. Thailand Global Autoimmune Disease Testing Market
- 16.11.1. Country Segmental Analysis
- 16.11.2. Test Type
- 16.11.3. Disease Type
- 16.11.4. Product Type
- 16.11.5. Technology
- 16.11.6. Sample Type
- 16.11.7. Method Type
- 16.11.8. End User
- 16.12. Vietnam Global Autoimmune Disease Testing Market
- 16.12.1. Country Segmental Analysis
- 16.12.2. Test Type
- 16.12.3. Disease Type
- 16.12.4. Product Type
- 16.12.5. Technology
- 16.12.6. Sample Type
- 16.12.7. Method Type
- 16.12.8. End User
- 16.13. Rest of Asia Pacific Global Autoimmune Disease Testing Market
- 16.13.1. Country Segmental Analysis
- 16.13.2. Test Type
- 16.13.3. Disease Type
- 16.13.4. Product Type
- 16.13.5. Technology
- 16.13.6. Sample Type
- 16.13.7. Method Type
- 16.13.8. End User
- 17. Middle East Global Autoimmune Disease Testing Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Test Type
- 17.3.2. Disease Type
- 17.3.3. Product Type
- 17.3.4. Technology
- 17.3.5. Sample Type
- 17.3.6. Method Type
- 17.3.7. End User
- 17.3.8. Country
- 17.3.8.1. Turkey
- 17.3.8.2. UAE
- 17.3.8.3. Saudi Arabia
- 17.3.8.4. Israel
- 17.3.8.5. Rest of Middle East
- 17.4. Turkey Global Autoimmune Disease Testing Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Test Type
- 17.4.3. Disease Type
- 17.4.4. Product Type
- 17.4.5. Technology
- 17.4.6. Sample Type
- 17.4.7. Method Type
- 17.4.8. End User
- 17.5. UAE Global Autoimmune Disease Testing Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Test Type
- 17.5.3. Disease Type
- 17.5.4. Product Type
- 17.5.5. Technology
- 17.5.6. Sample Type
- 17.5.7. Method Type
- 17.5.8. End User
- 17.6. Saudi Arabia Global Autoimmune Disease Testing Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Test Type
- 17.6.3. Disease Type
- 17.6.4. Product Type
- 17.6.5. Technology
- 17.6.6. Sample Type
- 17.6.7. Method Type
- 17.6.8. End User
- 17.7. Israel Global Autoimmune Disease Testing Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Test Type
- 17.7.3. Disease Type
- 17.7.4. Product Type
- 17.7.5. Technology
- 17.7.6. Sample Type
- 17.7.7. Method Type
- 17.7.8. End User
- 17.8. Rest of Middle East Global Autoimmune Disease Testing Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Test Type
- 17.8.3. Disease Type
- 17.8.4. Product Type
- 17.8.5. Technology
- 17.8.6. Sample Type
- 17.8.7. Method Type
- 17.8.8. End User
- 18. Africa Global Autoimmune Disease Testing Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Test Type
- 18.3.2. Disease Type
- 18.3.3. Product Type
- 18.3.4. Technology
- 18.3.5. Sample Type
- 18.3.6. Method Type
- 18.3.7. End User
- 18.3.8. Country
- 18.3.8.1. South Africa
- 18.3.8.2. Egypt
- 18.3.8.3. Nigeria
- 18.3.8.4. Algeria
- 18.3.8.5. Rest of Africa
- 18.4. South Africa Global Autoimmune Disease Testing Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Test Type
- 18.4.3. Disease Type
- 18.4.4. Product Type
- 18.4.5. Technology
- 18.4.6. Sample Type
- 18.4.7. Method Type
- 18.4.8. End User
- 18.5. Egypt Global Autoimmune Disease Testing Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Test Type
- 18.5.3. Disease Type
- 18.5.4. Product Type
- 18.5.5. Technology
- 18.5.6. Sample Type
- 18.5.7. Method Type
- 18.5.8. End User
- 18.6. Nigeria Global Autoimmune Disease Testing Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Test Type
- 18.6.3. Disease Type
- 18.6.4. Product Type
- 18.6.5. Technology
- 18.6.6. Sample Type
- 18.6.7. Method Type
- 18.6.8. End User
- 18.7. Algeria Global Autoimmune Disease Testing Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Test Type
- 18.7.3. Disease Type
- 18.7.4. Product Type
- 18.7.5. Technology
- 18.7.6. Sample Type
- 18.7.7. Method Type
- 18.7.8. End User
- 18.8. Rest of Africa Global Autoimmune Disease Testing Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Test Type
- 18.8.3. Disease Type
- 18.8.4. Product Type
- 18.8.5. Technology
- 18.8.6. Sample Type
- 18.8.7. Method Type
- 18.8.8. End User
- 19. South America Global Autoimmune Disease Testing Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Central and South Africa Global Autoimmune Disease Testing Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 19.3.1. Test Type
- 19.3.2. Disease Type
- 19.3.3. Product Type
- 19.3.4. Technology
- 19.3.5. Sample Type
- 19.3.6. Method Type
- 19.3.7. End User
- 19.3.8. Country
- 19.3.8.1. Brazil
- 19.3.8.2. Argentina
- 19.3.8.3. Rest of South America
- 19.4. Brazil Global Autoimmune Disease Testing Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Test Type
- 19.4.3. Disease Type
- 19.4.4. Product Type
- 19.4.5. Technology
- 19.4.6. Sample Type
- 19.4.7. Method Type
- 19.4.8. End User
- 19.5. Argentina Global Autoimmune Disease Testing Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Test Type
- 19.5.3. Disease Type
- 19.5.4. Product Type
- 19.5.5. Technology
- 19.5.6. Sample Type
- 19.5.7. Method Type
- 19.5.8. End User
- 19.6. Rest of South America Global Autoimmune Disease Testing Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Test Type
- 19.6.3. Disease Type
- 19.6.4. Product Type
- 19.6.5. Technology
- 19.6.6. Sample Type
- 19.6.7. Method Type
- 19.6.8. End User
- 20. Key Players/ Company Profile
- 20.1. Abbott Laboratories
- 20.1.1. Company Details/ Overview
- 20.1.2. Company Financials
- 20.1.3. Key Customers and Competitors
- 20.1.4. Business/ Industry Portfolio
- 20.1.5. Product Portfolio/ Specification Details
- 20.1.6. Pricing Data
- 20.1.7. Strategic Overview
- 20.1.8. Recent Developments
- 20.2. Beckman Coulter, Inc.
- 20.3. bioMérieux SA
- 20.4. Bio-Rad Laboratories, Inc.
- 20.5. Danaher Corporation
- 20.6. EUROIMMUN AG
- 20.7. Exagen Inc.
- 20.8. F. Hoffmann-La Roche Ltd
- 20.9. Grifols, S.A.
- 20.10. Hologic, Inc.
- 20.11. Inova Diagnostics, Inc.
- 20.12. Myriad Genetics, Inc.
- 20.13. ORGENTEC Diagnostika GmbH
- 20.14. Phadia AB (a Thermo Fisher brand)
- 20.15. Quest Diagnostics Incorporated
- 20.16. Siemens Healthineers
- 20.17. SRL Diagnostics
- 20.18. Thermo Fisher Scientific Inc.
- 20.19. Trinity Biotech plc
- 20.20. Werfen Life Group
- 20.21. Other key Players
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography